These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 21287602)

  • 1. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.
    Marras C; McDermott MP; Marek K; Rochon P; Naglie G; Tanner CM; Rudolph A; Shoulson I; Lang AE;
    Mov Disord; 2011 Mar; 26(4):608-13. PubMed ID: 21287602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.
    Marras C; Lang AE; Eberly SW; Oakes D; Fahn S; Schwid SR; Hyson C; Shoulson I;
    Mov Disord; 2009 Dec; 24(16):2370-8. PubMed ID: 19908310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease.
    Paumier KL; Siderowf AD; Auinger P; Oakes D; Madhavan L; Espay AJ; Revilla FJ; Collier TJ;
    Mov Disord; 2012 Jun; 27(7):880-7. PubMed ID: 22555881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.
    Marras C; McDermott MP; Rochon PA; Tanner CM; Naglie G; Lang AE;
    Mov Disord; 2008 Apr; 23(5):653-9; quiz 776. PubMed ID: 18076084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of motor impairment and disability in Parkinson disease: a population-based study.
    Alves G; Wentzel-Larsen T; Aarsland D; Larsen JP
    Neurology; 2005 Nov; 65(9):1436-41. PubMed ID: 16275832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.
    Merola A; Zibetti M; Angrisano S; Rizzi L; Ricchi V; Artusi CA; Lanotte M; Rizzone MG; Lopiano L
    Brain; 2011 Jul; 134(Pt 7):2074-84. PubMed ID: 21666262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal clinically important change on the unified Parkinson's disease rating scale.
    Schrag A; Sampaio C; Counsell N; Poewe W
    Mov Disord; 2006 Aug; 21(8):1200-7. PubMed ID: 16673410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.
    Parkinson Study Group PRECEPT Investigators
    Neurology; 2007 Oct; 69(15):1480-90. PubMed ID: 17881719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors of subthalamic stimulation in Parkinson's disease: a comparative study between short- and long-term effects.
    Tsai ST; Lin SH; Chou YC; Pan YH; Hung HY; Li CW; Lin SZ; Chen SY
    Stereotact Funct Neurosurg; 2009; 87(4):241-8. PubMed ID: 19556833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.
    Marras C; McDermott MP; Rochon PA; Tanner CM; Naglie G; Rudolph A; Lang AE;
    Neurology; 2005 Jan; 64(1):87-93. PubMed ID: 15642909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort.
    Wills AM; Li R; Pérez A; Ren X; Boyd J;
    J Neurol; 2017 Aug; 264(8):1746-1753. PubMed ID: 28712000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group.
    Ann Neurol; 1996 Jan; 39(1):29-36. PubMed ID: 8572663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
    Winge K; Werdelin LM; Nielsen KK; Stimpel H
    Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selegiline use is associated with a slower progression in early Parkinson's disease as evaluated by Hoehn and Yahr Stage transition times.
    Zhao YJ; Wee HL; Au WL; Seah SH; Luo N; Li SC; Tan LC
    Parkinsonism Relat Disord; 2011 Mar; 17(3):194-7. PubMed ID: 21159539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The factor structure of the UPDRS as an index of disease progression in Parkinson's disease.
    Evans JR; Mason SL; Williams-Gray CH; Foltynie T; Trotter M; Barker RA
    J Parkinsons Dis; 2011; 1(1):75-82. PubMed ID: 23939258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.